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N-Myristoyltransferase inhibition as a tool for antileishmanial drug discovery: Use in high-
throughput, de novo, and piggyback strategies for drug development 
John Anthony Kavouris M.S. 
University of Pittsburgh, 2014 
Leishmaniasis is a disease caused by the Leishmania genus of protozoan parasites, and 
spread by the phlebotomine genus of sandfly. The disease is caused by at least 20 different 
species of Leishmania parasites, and manifests itself in three forms: cutaneous, mucocutaneous, 
and most severely, visceral leishmaniasis. Current chemotherapeutic treatments for leishmaniasis 
are limited by parasite resistance to existing drugs, highly toxic side effects, and high cost of 
treatment.  As a neglected tropical disease, there has been relatively little research toward new 
drugs, despite a large need, comprising 1.3m new cases and 20,000-50,000 deaths annually. 
Fortunately, although there is a wide variety in species causing the disease, visceral 
leishmaniasis is largely caused by a single species of parasite, Leishmania donovani, greatly 
simplifying the search for drugs against the most dangerous form of the disease. The whole 
genome of the species has been sequenced, and many crystal structures of key proteins have been 
elucidated. Specifically, N-myristoyltransferase (NMT) has emerged as a promising enzyme for 
target-based antileishmanial drug development, with a wide array of tools available for any level 
of drug discovery: in silico modeling and docking, enzyme specific assays for protozoan and 
human isoforms, high throughput in vitro assays against both the parasite itself and infected host 
cells, and animal models of the disease. However, with L. donovani NMT as a newer target, 
research has yet to utilize all of these individual elements synergistically with themselves, or 
 v 
with related studies in different parasite species. Combined analysis of these methods can yield a 
more efficient search for antileishmanials, regardless of screening type. 
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1.0  LEISHMANIASIS: DISEASE OVERVIEW AND NEED FOR TREATMENT 
Leishmaniasis is a disease caused by the Leishmania genus of protozoan parasites and spread by 
the phlebotomine genus of sandfly. The disease is endemic to tropical and sub-tropical countries, 
predominantly affecting the developing world.
1
 Major risk factors of the disease include negative 
socioeconomic conditions, malnutrition, population mobility and environmental changes, all 
conditions frequently encountered in the tropics. 
1.1.1 Disease burden 
 Leishmaniasis affects approximately 12 million people worldwide, with approximately 2 
million new cases and 20-50 thousand deaths annually. After malaria, it is the second highest 
parasitic killer. The disease manifests itself in a variety of forms: cutaneous, mucocutaneous, and 
visceral. Cutaneous results in open sores that eventually heal on their own within a few months 
to a year and a half, but scarring can occur. Mucocutaneous can affect the skin and mucous 
membranes (nose, mouth, throat), yielding sores that typically heal, with scarring and potential 
tissue damage. Visceral leishmaniasis (VL, also known as ‘kala-azar’), the most serious form, is 
caused by parasite migration to internal organs and is fatal if left untreated.
2
 Even with treatment, 
visceral leishmaniasis can result in organ damage. Further complications can also arise from 
leishmaniasis infection, including post kala-azar dermal leishmaniasis (PKDL) in which the 
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parasite infection recurs affecting the skin and co-infection in patients with HIV. Leishmaniasis 
is recognized as a neglected tropical disease (NTD).
3-4
 While the definition criteria vary among 
different health organizations, NTDs are generally endemic to low-income areas of the tropics, 
and that lack adequate available treatments. 
 Current treatments for leishmaniasis have improved in the last decade with the introduction 
of Miltefosine as the first orally-available therapy, but existing treatments are limited by factors 
of cost, oral availability, toxicity, and parasite resistance.
5
 Unfortunately, parasite resistance is 
not only a problem of older treatments such as pentavalent antimonials, but instances of 
resistance have also been shown for more recently developed treatments as well.
6-9
 The Drugs 
for Neglected Disease Initiative (DNDi) is non-profit organization devoted to developing 
treatments for neglected diseases, and includes a large variety of industry, governmental, and 
academic partners, with a focus on collaborative projects. Based on DNDi efforts, the treatment 
options for leishmaniasis are improving, but slowly.
10
 Currently, the most advanced therapies 
focuses on combination of existing drugs.
11
 Only one novel chemotheraputic, sitamiquine, is 
currently in development through GSK/Walter Reed Army Institute that is currently in phase II 
clinical trials. Other treatments under development are oral and topical formulations of existing 
drug amphotericin B, which has previously only available via IV therapy and is highly toxic. 
Also, fexinidazole, a human African trypanosomaisis inhibitor, is beginning phase II trials as a 
treatment for L. donovani infection as well.
12
 
 Palatnik-de-Sousa and Kedzierski have both proposed that the parasite’s biology may 
provide a route to vaccination and there is one candidate vaccine currently in Phase I trials. 
13-15
 
Nevertheless, until a range of treatments is approved for use, a need persists for the pre-clinical 
development of antileishmanials that meet all the desired criteria for safety, efficacy, and cost. 
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1.1.2 Complications to developing treatments  
Leishmania parasites are transferred to mammalian hosts via the bite of infected female 
phebotomine sandflies, depicted in Figure 1.
16
 Within the sandfly midgut, the parasites exist as 
motile metacyclic promastigotes, eventually migrating to the stomodeal valve. When the fly bites 
a host, promastigote transmission occurs, however, the vector is not yet infective. Promastigotes 
invade mammalian macrophages where they are phagocytized into amastigotes, the spread of 
which by infection and replication within host cells affects the surrounding tissue. If transmitted 
back to the sandfly, the amastigotes revert back to procyclic promastigotes in the absence of host 
macrophage cells. Undergoing cell division, parasites are considered metacyclic promastigotes, 
thereby restarting the cycle. 
 
Figure 1. Leishmania parasite life cycle. 
Image used from public domain. 
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 In addition to the multiple parasite forms, the number of Leishmania species that 
cause the disease complicates disease progression, expression, and treatment development; over 
20 species of parasite have been shown to cause the differing forms of the disease. This 
biological diversity accounts for the phenotypic differences in disease manifestation. Most 
species are associated with a specific form of illness, but occasionally, individual species 
themselves will cause different manifestations.
17
 Fortunately, a wide array of genomic and 
proteomic data is known for leishmania parasites, including completely sequenced genomes of 
several species, the characterization of many proteins necessary for parasite function, and the 
solution of several crystal structures of relevant proteins.
18-20
 The wealth of data regarding 
protein structure and function offers some mechanistic insight into known NMT inhibitors that 
are effective across multiple Leishmania species.
21
 However, the number and variety of species 
also illustrates the complexity of generating broad-spectrum antileishmanial theraputics. 
 Drug development for leishmaniasis has been assisted by related research on other 
trypanosomatid diseases that include Trypanosoma brucei, (human African trypanomaisis, 
“sleeping sickness”), and T. cruzi (South American trypanosomiasis, “Chagas diease”).22 Similar 
drugs/targets have also been identified in certain fungal and bacterial infections, and in the 
Plasmodium genus, responsible for malaria.
23
 These species share biological similarities with 
Leishmania spp. and offer a large dataset related to development of antileishmanials, including 
crystal structures of related target proteins, and examples of cross-species inhibition by single 
compounds.
24
 Again, the additional information helps the understanding of existing cross-species 
drug efficacy, but only further convolutes an effort for development of novel broad-spectrum 
antitrypanosomal drugs. It is worth noting that, despite certain macromolecular similarities 
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between species, species pathology ultimately affects drug development as well. Considerations 
for HAT drug development must account for blood-brain-barrier penetration to treat the infected 
host. Under similar preliminary screening conditions, this would be an added complication for 
HAT inhibitors, but is absent from Leishmania inhibitor design considerations. 
 The number and complexity of leishmaniasis manifestations renders the disease 
an incredibly difficult candidate for rational drug design. Although a potent treatment against all 
forms of the disease may be unlikely, visceral leishmaniasis infection is both a major contributor 
to the global mortality and morbidity, and surprisingly well suited for rational drug design. Of 
the global leishmaniasis disease burden, visceral leishmaniasis accounts for approximately 
200,000-400,000 new infections, and 20,000-40,000 deaths per year.
25-26
 
1.1.3 Visceral leishmanias as focus for treatment 
 Treatment of visceral leishmaniasis is aided by the high degree of similarity 
between causative species. Visceral leishmaniasis is largely cited as caused by the species L. 
donovani, and occasionally, by L. infantum. In fact, four individual Leishmania species have 
been proposed as causes for VL: L. donovani, L. infantum, L. chagasi, and L. archibaldi.
27
 
Despite the general classification as separate species, the distinction largely arises from 
geographic origins of each sample. The perceived differences between these taxons are so minute 
that markers of differentiation are often unreliable.
28-29
 As such, these four species are broadly 
referred to as the ‘donovani complex.’ Analysis of the species has accounted for small genetic 
differences and has been used to trace disease spread and evolution, however, researchers 
concluded that not enough genetic variation is present within current available data to warrant 
this species differentiation. Instead, a corrected differentiation of only two species is proposed: 
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donovani and infantum.
30
 While differences in pathology between the two species have been 
studied, many considerations for rational drug design remain largely similar.
31
 Structural 
characteristics of drug target enzymes are highly conserved across reported species, typically 
with >95% sequence or structure similarities, as applicable. As such, inhibitors of both species 
are likely viable through a single drug discovery campaign. However, given similar species with 
same clinical outcome of VL, cross-validation of known inhibitors on both species is currently 
limited. 
 Elements are currently in place to facilitate scalable, target-based, rational drug 
design toward inhibitors of visceral leishmaniasis. Several proteins of the Leishmania donovani 
complex have been investigated as potential therapeutic targets and, in particular, N-
myristoyltransferase (NMT) has emerged as a promising one. This target offers multiple design 
motifs such as in silico methods using crystallographic data, enzymatic assay, in vitro assays, 
and availability of in vivo disease models. The three screening methods (in silico, enzymatic, in 
vitro) may be run in high-throughput or high-content applications, aided by automation to 
facilitate the screening of large sized compound libraries. Furthermore, techniques relevant to 
NMT-based drug development may be arranged for de novo drug design specifically targeting L. 
donovani NMT, as an additional element of ‘target-free’* screening to identify an affected target 
and improve hit optimization, or as a ‘piggyback’ approach based on existing NMT inhibitors in 
other species. Despite the availability and scope of these methods, their combined use is 
surprisingly limited. A discussion of available methods for drug development, their existing 
applications, and prospective improvements or combinations is presented herein.  
                                                 
*
 ‘Target-free,’ or phenotypic screening tests potential inhibitors for protozoan growth 
inhibition and limited human toxicity, irrespective of molecular targets affected. 
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2.0  N-MYRISTOYLTRANSFERASE 
Protein myristoylation is an essential function in eukaryotes that occurs via the addition 
of a myristoyl group to the N-glycine terminus of a set of proteins.
32-33
 The myristoyl group, 
derived from myristic acid (n-tetradecanoic acid), is a 14-carbon saturated fatty acid serving as a 
long, hydrophobic tail in a variety of functions, including protein-protein interactions, membrane 
targeting, signal transduction, and apoptosis.
34-35
 The amide bond formation is catalyzed by the 
enzyme myristoyl-CoA protein N-myristoyltransferase (NMT) that occurs as both a post- and, 
more typically, co-translational modification.
36
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Figure 2: Protein mryistoylation as a co-translational process. 
Image used under Creative Commons license.
37
 
 
The binding events required for protein substrate myristoylation have been thoroughly 
characterized and includes an understanding of substrate specificities for both the myristoyl and 
protein binding sites. The mechanism proceeds via an “ordered bi bi mechanism,” in which 
myristoyl-CoA first binds to the apo-enzyme.
38
 The myristoyl-CoA binding induces an allosteric 
effect on the enzyme that positions the CoA as a functional part of the protein binding site. The 
myristoyl group transfer is facilitated by the attack of the incoming N-terminal glycine on the 
myristoyl-CoA thioester, shown in Figure 2. After the transfer, the free CoA is released first, 
allowing the enzyme conformation to relax and release the myristoylated substrate protein; the 
O
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full catalytic cycle is depicted in Figure 3. As a treatment for disease, cell death is the desired 
response, achieved through inhibition of the enzyme and disrupting critical cellular processes.  
 
Figure 3: Myristoylation catalytic cycle. 
Reprinted with permission from Bowyer, P. W.; Tate, E. W.; Leatherbarrow, R. J.; Holder, A. A.; Smith, D. 
F.; Brown, K. A., N-Myristoyltransferase: A prospective drug target for protozoan parasites. ChemMedChem 2008, 
3 (3), 402-408. 
2.1 NMT STRUCTURE, FUNCTION, AND SUBSTRATES 
The effects of different coenzymes on substrate binding have not been thoroughly studied, but 
myristate substitutions have been investigated in different species.
39
 Generally, specific 
recognition of myristoyl-CoA has been shown, but the specific acyl-CoA bound to the enzyme 
has been shown to affect substrate peptide binding. Chain length has been implicated as the 
major driving force for this specificity, followed by hydrophobicity. For example, 13- and 15-
carbon fatty acid substrates have been shown to bind competitively with myristoyl-CoA, but this 
is largely irrelevant in vivo, as these fatty acids are rarely found in eukaryotes.
40
 The closest 
natural/commonly occurring fatty acid, the 16-carbon chain palmitoyl-CoA, can compete with 
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the myristate binding.
41
 While a poor substrate, it is found in much greater intracellular 
concentrations, yet NMT function is still determined by the myristate. Overall, the enzyme 
shows little tolerance for alternate acyl-CoA substrates in vivo, and the myristoyl-CoA binding 
site is highly conserved across species studied. 
 Unlike the myristoyl-CoA binding site, the protein binding site is not highly conserved 
across species, allowing for substrate specificity for protein myristoylation and species-specific 
inhibition of the NMT enzyme. Substrate specificity is accomplished by recognition of N-
terminal amino acid residues within the substrate protein with as many as 17 terminal residues 
responsible for substrate recognition.
42-43
 These 17 residues are split into three regions; region 1 
consists of the first 6 residues, which fit within the binding pocket, and must terminate with a 
glycine; region 2 consists of the next 6 residues, interacting with the surface of the protein 
adjacent to the binding pocket, typically consisting of smaller, polar residues; region 3 consists 
of the final 5 amino acids typically recognized by the enzyme, and is usually comprised of 
increasingly hydrophilic residues. The enzyme’s broader recognition of several substrate 
residues allows for specificity of proteins to be myristoylated, but the existence of a specific, 
well-defined binding pocket allows for enzyme inhibition by small molecules. Competitive 
inhibition of protein myristoylation by small molecule binding to the substrate pocket has been 
confirmed by kinetic studies, suggesting the viability of NMT inhibition as a therapeutic 
target.
44-45
  
2.2 NMT UTILITY AS A LEISHMANIASIS DRUG TARGET 
 Several distinctions between mammalian and protozoan NMTs have been identified and 
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may be exploited for the treatment of protozoan diseases, such as leishmaniasis. Mammals all 
possess two NMT isozymes, NMT1, and NMT2, each exhibiting slightly different protein 
substrate specificity, but both are highly similar to one-another and highly conserved across 
species. For example, human NMT1 (Hs1NMT), and Hs2NMT share 77% sequence identity. 
Homologues are, of course, expressed in mice, and the mouse NMT1 and NMT2 share 97% and 
96% sequence identity with the respective human isozyme.
46
 This sequence homology allows for 
accurate modeling of NMT inhibition in mouse models of infection. 
 The genus Leishmania only synthesizes one NMT isozyme which is sufficiently different 
from the human forms to allow for specific inhibition. For example, the L. donovani NMT 
(LdNMT) only shares 42% sequence identity with Hs1NMT and highly selective inhibition of 
LdNMT over both human NMTs has been demonstrated. The NMTs of leishmania parasites are 
highly conserved across different parasite species with L. major sharing 97, 96, and 96% 
sequence identity with L. donovani, L. infantum, and L. mexicana, respectively. Residues 
associated with the predicted peptide binding groove are fully conserved between L. donovani, L. 
major, L. infantum and L. braziliensis.
47
 The combined similarities of parasite NMTs and 
differences from host NMTs suggest that, despite a focus on treatment of visceral leishmaniasis, 
expansion of a drug discovery program to successfully combat more forms of the disease may be 
within reach.  
 N-Myristoyltransferase inhibition has been demonstrated in a variety of other organisms, 
typically as a means to treat infectious disease. Closely related to antileishmanial drug 
development, NMT inhibition is also currently under investigation as a treatment for other 
trypanosomal diseases.
24, 48-49
 Initial determinations of NMT structure and function was 
performed in yeasts, such as Candida albicans, commonly responsible for infection in the 
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immunocompromised. Several anti-fungal NMT inhibitors have been identified.
50
 NMT over 
expression has also been linked to certain cancers, and NMT enzyme suppression has been 
proposed as a treatment.
51-53
 However, cancer treatments via NMT inhibition is distinct from 
other NMT inhibitor studies in that cancer cell inhibition would rely on selectivity between the 
two individual human NMT isozymes, rather than selectivity between human and infection 
forms. Ultimately, a continually expanding portfolio of known NMT inhibitors offers structure-
based insight toward the design of novel inhibitors and starting points for piggyback drug design. 
 Aside from the enzyme’s mechanism and function, a great deal of structural 
information is known about NMTs beyond basic sequence information. A large number of NMT 
enzyme structures have been elucidated by X-ray crystallography, most in high resolution 
(~1.5Å resolution, high degree of completeness). A large majority of the crystal structures 
include myristoyl-CoA bound to the protein, offering the allosteric conformation relevant for 
inhibitor binding, rather than the apo-enzyme. Many species include multiple PDB entries, with 
one structure crystallized with an empty binding pocket, and at least one entry with a known 
small molecule NMT inhibitor bound, including Leishmania major (Figure 4), human NMT1, 
Saccharomyces cerevisiae,  and Candida albicans.
50, 54-55
 With respect to visceral leishmaniasis, 
the Leishmania donovani NMT has been crystallized with a myristoyl-CoA analog (S-(2-
oxo)pentadecyl-CoA) to avoid hydrolysis, however no structure with a bound inhibitor has yet 
been crystallized (PDB: 2WUU).
47
 Accurate structural data, allows for easily accessible in silico 
studies of protein-inhibitor interaction. Furthermore, known inhibitors bound to the crystal 
structures serve as means to validate computational docking models. NMT inhibition has been 
biologically validated as a target in the Plasmodium genus.
56
 In L. donovani NMT is not fully 
biologically validated, as sufficient data regarding myristoylated proteins within the parasite, or 
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specific downstream effects of NMT inhibition. Nevertheless, NMT has been shown to be an 
essential enzyme for parasite survival, and inhibition of the enzyme is toxic to kinetoplastid 
parasites.  
 
Figure 4: Representative NMT inhibitor and crystal structure. 
a) Inhibitor. b) L. major NMT crystal structure and computed surface. Myristoyl-CoA (blue C atoms), 
inhibitor (orange C atoms). Reprinted with permission from David Robinson, University of Dundee.
57
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3.0  SCREENING METHODS 
3.1 IN VITRO METHODS 
A variety of in vitro cell culture and analysis methods have been shown as useful model systems 
for leishmaniasis infection.
58-59
 These methods are scalable, enabling large compound libraries to 
be assayed via high throughput screening.
60
 Further analysis of hit compound viability as a lead 
is possible through related assays, such as toxicity and metabolic stability.  
3.1.1 Enzymatic assays 
 For direct quantification of NMT-specific inhibition, many enzymatic assays are available. 
Most assays rely on the detection of radio-labeled material incorporated into the product, through 
techniques such as scintillation proximity assays (SPA).
61
 For this assay and others, recombinant 
NMT proteins can be over-expressed and purified from E. coli. Myristoyl-CoA is introduced to 
the purified protein, wherein the myristoyl group has been modified by tritiation (replacement of 
hydrogen with radioactive tritium). Instead of a complete protein to be myristoylated, a model 
peptide substrate is constructed by solid-phase peptide synthesis (SPPS). The sequences of these 
model peptides are designed based on N-terminal (~8-residue) segments from known protein 
substrates of NMT. Biotin is applied to the C-terminus of the chain as an affinity tag. Both 
modified substrates (radio-labeled myristoyl-CoA and biotinylated peptide) are mixed with the 
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enzyme, and myristoylation occurs. A streptavidin tag held on a solid support encapsulating a 
scintillant is then added to the reaction. After this addition, the now radio-labeled peptide will 
migrate to the solid-support as a result of biotin-streptavidin binding, and result in the emission 
of photons by the scintillant; the full assay scheme is shown in Figure 5. Tritium is well suited 
for this task, as the path-length of the emitted ß-particle is short enough (1.5 µm) that non-
specific emission from unreacted starting material will not reach the scintillation bead, meaning 
the reaction does not have to be purified before measuring enzyme activity. The emitted photons, 
and thereby reaction progress, can be monitored via scintillation counter. This process has been 
used for a wide variety of NMT isozymes, including human NMT1 and 2, L. donovani, L. major, 
T. brucei, T. cruzi, and P. falciparum.
24, 48, 62
 The process can also be automated through the use 
of 96- or 384-well plate plates for high-throughput screening. 
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Figure 5: Scintillation proximity assay.  
Step 1: Radio-labeleld myristate is added to the biotin-tagged protein mimetic. Step 2: The peptide and 
radio-label are attached to the scintillant bead by the biotin-streptavidin interaction. Step 3: The radio-label is 
sufficiently close to the scintillant to cause a photon emission. Reprinted with permission from Bowyer, P. W.; Tate, 
E. W.; Leatherbarrow, R. J.; Holder, A. A.; Smith, D. F.; Brown, K. A., N-Myristoyltransferase: A prospective drug 
target for protozoan parasites. ChemMedChem 2008, 3 (3), 402-408. 
3.1.2 Cellular assay 
 Several cellular based assays are also available to determine antileishmanial activity. These 
include culture and inhibition of promastigotes, axenic amastigotes, and intracellular 
amastigotes. Each of these methods may be used in a target-free screening of inhibitors, but they 
may also be incorporated with NMT-based drug discovery effort, as NMT is constitutively 
produced at all stages of parasite development.
48
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 Promastigote-based cellular assays are the most straightforward of the three cell-based 
assays. Promastigotes are grown in a media, potential inhibitors are introduced at suitable 
concentrations, and growth inhibition is determined.
63
 High-throughput applications are available 
utilizing a plate reader for analysis of cell growth via fluorescent staining, with positive and 
negative controls (typically amphotericin B, and 1% DMSO, respectively). While promastigotes 
are often assayed for comparative purposes, their use is waning, as techniques for the high-
throughput screening of more biologically relevant parasite forms has become commonplace. 
 Axenic amastigote screening provides a more biologically relevant assay than 
promastigotes, since the former is the active parasite found within host mammals.
64-65
 Screening 
is accomplished much the same way as with promastigotes in terms of controls, and hit 
identification by fluorescence. However, the actual growth of the parasites differs, as they must 
be chemically induced to continue multiplying as amastigotes, rather than revert to the 
promastigote form. This is accomplished via manipulation of pH to mimic macrophage 
conditions, and occasionally by the inclusion of 5% CO2 in the atmosphere, or incubation of cells 
at biologically relevant temperatures (37 ºC). 
 Screening compounds against intracellular amastigotes provides the best in vitro similarity 
to conditions found in vivo.
66-67
 In this method, promastigote cultures are allowed to infect 
macrophage differentiated host cells in growth media. After a period of initial infection, the non-
internalized promastigotes are rinsed away with a buffer, and the parasites are allowed to 
continue to grow under the presence of test compounds, or controls. Chemical differentiation of 
the host cells into macrophages is required for two reasons - first, the macrophage best mimics 
the in vivo context for a host infection, and second, without differentiation to non-dividing 
macrophages, parasitized cells would be overrun by replicating cells. THP-1 (human acute 
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leukemia monocyte) cells are most often used for this purpose. Determination of inhibitor 
activity is accomplished by visualization with a fluorescent DNA-binding stain. Areas rich in 
DNA will fluoresce, predominantly the THP-1 cell nucleus, and parasite kinetoplasts. The 
difference in size between these two structures may be exploited for high-content screening. One 
assay yields not only a ratio of parasites to host cells, but also a quantification of host cells in 
each sample well to serve as a measure of toxicity induced by the compounds. These 
measurements can be taken by automated fluorescence microscopy, but require a software suite 
for the automated/accurate image analysis.
68
 
3.1.3 Secondary screening 
 After hit compounds are identified, several other in vitro methods have been used to assist 
in lead identification as secondary screens. If not part of a the primary screen, assay hits may be 
tested independently against uninfected THP-1 cells to determine toxicity. Metabolic stability is 
also an important aspect for lead compound identification and optimization, as even the most 
potent hit is ineffective if metabolized too quickly.
69
 Preliminary metabolic data may be gathered 
by subjecting the test compound to either rat or human liver microsomal stability assay. As a 
final consideration in lead identification and optimization, hit compounds may be screened 
against cytochrome P450, to avoid potential drug-drug interactions.
70
 
3.1.4 Screen analysis and validity 
 Large scale screening methods must provide a reliable means to identify biologically active 
compounds from a large compound library, with assays performed singly (rarely in duplicate or 
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triplicate). A statistical method for determination of assay quality has been proposed, yielding a 
dimensionless coefficient called the Z-factor, or Z-score (Equation 1).
71
 A Z-factor of 1 indicates 
an ideal assay, with standard deviations of zero, and infinite dynamic range. Typically Z-factors 
between 1 and   0.5 indicate a good quality assay, with a large separation band between hits and 
inactive compounds.  
           
 (     )
|     |
 
Equation 1: Z-Factor for HTS validity 
σ: standard deviation, μ: mean, p: positive control, n: negative control 
3.2 IN VIVO MODELS OF VISCERAL LEISHMANIASIS 
 After identification and optimization of hit compounds through in vitro methods, animal 
models are required to better mimic infection and treatment in mammalian hosts. For developing 
new chemotherapies, in vivo models serve to confirm compound activity determined from 
cellular and enzymatic assays, as well as provide information regarding administration routes, 
distribution, metabolism, excretion, and toxicity (ADMET). Several species have been studied as 
hosts for the L. donovani parasite as models for visceral leishmanias.
59
 Rodents, canines, and 
non-human primates have all been used for this task. 
 Rodent models are the most accessible models of L. donovani infection of a mammalian 
host. A variety of species have been studied, including C57BL/6 mouse, and Syrian golden 
hamster, but the BALB/c mouse model is most common.
72
 Canine models of the disease have 
also been used in studies of parasite biology, but with little emphasis for use on development of 
chemotheraputics.
59
 Establishing canines as accurate models is important nonetheless, as they 
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have been shown to exhibit closer disease pathology to humans than available in rodent models. 
Also, the study of leishmaniasis in canines is useful to determine their role as host reservoirs for 
certain species of the parasite.
73
 Finally, non-human primates have been studied as the most 
advanced, human-like model of leishmaniasis. Many species of primate are quite resistant to 
Leishmania infection, however, the languor (Presbytis entellus) has been identified as a 
promising model system for human leishmaniasis infection. The languor is susceptible to a 
lasting VL infection, ultimately resulting in death, and displays the same pathogenesis and 
immune response as in humans, allowing for their use in the study of antileishmanial vaccine 
candidates.
74
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4.0  LIMITED STATE OF ANTILEISHMANIAL DEVELOPMENT 
A wide array of experimental tools are available for the study and development of leishmania-
specific NMT inhibitors, yet there is a surprising lack of synergy and cross validation among 
these models. Currently, target-free screening is gerally preferred to target-based design: many 
putative targets besides NMT are characterized (albeit in less detail), and target-free screening 
allows for testing compounds ‘holistically’ focusing on overall efficacy, independant of 
knowledge about a particular molecular target.
65-66, 69, 75-77
 Choice of parasitic form 
(promastigote, and axenic or intracellular amastigote) is non-trivial, but improvements in high-
throughput assays for the later stages of the life cycle have rendered promastigote assays fairly 
obsolete.
67, 78
 Axenic and intracellular amastigote models are more biologically relevant, and are 
available in for use in high-throughput applications. To date, several target-free HTS/HCS based 
screens for Leishmania inhibitors has been performed, with z-scores > .5, indicating good quality 
screens.
79
 These efforts have resulted in the identification of novel scaffolds, but no attempt has 
been made to associate hits with a specific target (either by in silico methods, or enzymatic 
assay).  
 One NMT-based HTS has been performed utilizing the scintillation proximity assay, 
against the Pfizer global representative library (~150,000 compounds).
62
 This screen successfully 
demonstrated the ability to selectively inhibit LdNMT over Hs1NMT (Figure 7), and identified 
several scaffolds for NMT inhibition, representatives shown in Figure 6. However, this screen 
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was not without shortcomings, such as a lack of testing in cellular assays to confirm bioactivity 
and selectivity of identified hits. Also, while each scaffold generated a series of ‘local’ hits, only 
inhibition data for top hits within each family was reported, rather than observed SAR. 
 
Figure 6: LdNMT assay hits and selectivities. 
 
Figure 7: Tunable selectivity between Ld and Hs1 NMT inhibition. 
Reprinted under Creative Commons license from Bell, A. S.; Mills, J. E.; Williams, G. P.; Brannigan, J. A.; 
Wilkinson, A. J.; Parkinson, T.; Leatherbarrow, R. J.; Tate, E. W.; Holder, A. A.; Smith, D. F., Selective inhibitors 
of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. 
PLoS Negl Trop Dis 2012, 6 (4), e1625.
80
 
 
 In silico analysis of antileishmanial NMT inhibitors is also limited. Despite the large 
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quantity of crystallographic data available for Leishmania spp. NMT enzymes, few detailed in 
silico docking or modeling studies have been published. Of the few studies available, many are 
not specific to NMT, but rather, focus on a cross-sectional docking study of inhibitors against a 
range of potential targets. Ogungbe, et al. have published two separate reports docking plant-
based phenolic compounds (stilbenoids, phenylpropanoids, flavonoids, quinones, etc) to a large 
series of crystal structures to determine potential targets.
81-82
 In either instance, a library of 
chemicals (some of which have shown broad antiparasitic activity) is docked to the array of 
structures, and energies reported. However, neither report offers a more in-depth analysis of the 
data, by way of rationalizing existing cellular assay data with docking results, or collaborative 
work to screen top computational hits against cellular or enzymatic assays. 
 Sobarzo-Sanchez et al. have studied a small series of oxoisoaporphine antileishmanials 
(Figure 8) in detail, providing in vitro, in vivo, and in silico analysis.
83
 Their aim was similar to 
Ogungbe’s work, but more successful in identifying potential targets. Utilizing 128 known 
Leishmania enzymes with docked ligands as the basis for a training dataset, the group utilized 
bioinformatic analysis (via ‘MARCH-INSIDE’ software) to determine 4 putative targets, 
including NMT. From these results, an NMT enzymatic assay could easily confirm 
oxoisoaporphines as NMT inhibitors, and provide a positive or negative training dataset for 
further in silico study of oxoisoaporphines. 
 
Figure 8: Oxoisoaporphine scaffold. 
 While NMT has been studied in leishmaniasis, and its inhibition has been shown as a 
means to combat parasite growth, the discovery of corresponding Leishmania NMT inhibitors is 
N
O
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limited. Simple efforts to utilize existing methods synergistically can increase the efficiency in 
which NMT inhibitors are discovered and optimized. 
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5.0  NMT STUDIES IN RELATED ORGANISMS 
As described previously, NMT enzyme activity has been proposed as a target for a variety of 
fungal and protozoan diseases, and a number of compounds have been reported to inhibit the 
NMT enzyme and disease growth. However, in comparison to Leishmania NMT inhibitors, 
NMT inhibition in other species has been studied in much greater detail, with inclusion of SAR, 
in silico, and crystallographic supporting data. Some relevant data with regard to cross-inhibition 
of Leishmania NMTs is occasionally discussed within these studies, but is rarely presented in 
context of SAR studies focusing on improving antileishmanial potency. It is not uncommon for 
large swaths of medicinal chemistry data to go unreported in scientific journals and only 
published in patents.
84
 This is no different for NMT inhibitors: while there is a lack of SAR data 
and discussion for antileishmanials presented within journal articles, certain data-sets can be 
found in related patents, but without relevant discussion. A variety of compound classes have 
been reported as NMT inhibitors in other species with some crossover studies on Leishmania 
spp, including benzofurans and similar heterocycles, pyrazole sulfonamides, quinolines, and 
peptides/peptidomimetics. These scaffolds and associated analyses can serve as starting points 
for piggyback drug development strategies.
85
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5.1.1 Benzofurans 
 Benzofurans, and associated compounds (benzothiazoles, benzothiophenes, indoles) are 
amongst the most studied NMT inhibitors, and this broad group of compounds has been used for 
piggyback hit generation/optimization across several species.
86-94
 QSAR studies have been 
performed on existing hit datasets to determine pharmacophore models, which have been 
computationally used to generate new prospective hits.
95-96
 In terms of activity-based SAR, a 
piggyback approach using the same or similar heterocyclic core is common amongst other types 
of disease, which is visually apparent between studies on different species.
97-98
 Despite the core 
similarities between inhibitors, each subsequent study has expanded around existing SAR 
(species specific), in continually good detail.
99
 Furthermore, many papers include 
crystallography data showing the binding pose of their top hit(s). However, no journal articles 
discuss the implications of these results with respect to the development of antileishmanials. 
 Benzofurans and furan-like compounds have been patented for use as NMT inhibitors of 
P. falciparum, and L. donovani. Despite a lack of reporting in primary literature sources, the 
patent features a SAR of 140 compounds with similar heterocyclic cores, and relevant IC50 
concentrations (SPA or fluorescence assay) for both L. donovani and P. falciparum.
100
 Of the 
compounds screened, 74 have been identified by the authors as ‘hits’ (< 5 µM IC50) against 
LdNMT. The most potent, shown below (Figure 9), possesses an IC50 of 0.01 µM. Unfortunately 
this hit was not screened against human NMT1 to determine selectivity. The most potent 
inhibitor with selectivity data displays 0.027 µM IC50 against LdNMT, and 1.00 µM IC50 
inhibition against Hs1NMT, roughly 40-fold selectivity favoring parasite isozyme inhibitions. 
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Figure 9: Benzofurans as NMT inhibitors. 
The most recently published study of this class of compounds investigated the use of 
substituted  benzothiophenes as inhibitors of P. falciparum and P. vivax (Figure 10). The study 
proposes ‘ligand efficiency dependent lipophilicity’ (LELP) as a single metric to assist in triage 
of molecules, and as a strong predictor of drug-likeness, utilizing compounds from the previous 
patent. Included are crystal structures of two inhibitors bound to P. vivax NMT, displaying 
complementary binding modes to previous characterizations. LELP optimization resulted in 
~100-fold increase in enzyme affinity.
101
 
 
Figure 10: LELP-optimized Plasmodium inhibitors and crystal structure with ligand. 
(PDB: 4CAF) Reprinted with permission from Rackham, M. D.; Brannigan, J. A.; Rangachari, K.; Meister, 
S.; Wilkinson, A. J.; Holder, A. A.; Leatherbarrow, R. J.; Tate, E. W., Design and synthesis of high affinity 
inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency 
dependent lipophilicity (LELP). J Med Chem 2014, 57 (6), 2773-2788. Copyright 2014 American Chemical Society. 
 
LELP is calculated as cLogP/LE. Ligand efficiency, LE = [−RTlog(Ki)]/(no. of heavy 
atoms). Ki values are calculated from the experimentally determined IC50 values, the substrate 
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concentration ([S]), and the Michaelis–Menten constant (Km) as described by the Cheng–Prusoff 
equation (Equation 2).
102
 Km values are used from previously experimentally determined 
constants. 
   
    
  
[ ]
  
 
Equation 2: Cheng-Prusoff equation 
[S] = substrate concentration 
5.1.2 Pyrazole sulfonamides 
 
Figure 11: Pyrazole sulfonamide NMT inhibitors and representative crystal structure. 
Reprinted with permission from Brand, S.; Cleghorn, L. A.; McElroy, S. P.; Robinson, D. A.; Smith, V. C.; 
Hallyburton, I.; Harrison, J. R.; Norcross, N. R.; Spinks, D.; Bayliss, T.; Norval, S.; Stojanovski, L.; Torrie, L. S.; 
Frearson, J. A.; Brenk, R.; Fairlamb, A. H.; Ferguson, M. A.; Read, K. D.; Wyatt, P. G.; Gilbert, I. H., Discovery of 
a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 2012, 55 (1), 140-152. 
Copyright 2011 American Chemical Society. 
 
Pyrazole sulfonamides are less ubiquitous than benzofuran-like molecules for NMT 
inhibition, but nevertheless, extensive SAR studies have been performed towards the inhibition 
of T. brucei, and T. cruzi parasites.
103-104
 Screening of ~60,000 compounds yielded an initial hit, 
and subsequently over 200 analogs were synthesized for further analysis.
103
 The initial hit, its 
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binding pose in a crystal structure, and optimized compound are shown in Figure 11. Studies on 
these analogs include corresponding selectivity data between TbNMT and Hs1NMT via SPA 
assay, and in vitro activity against T. brucei parasites. Beginning with an initial hit of 21 μM 
(IC50) against the T. brucei parasite, the optimizations culminated in a compound with 0.002 μM 
potency. The paper indicates cross-inhibition of L. major, however only inhibition by the 
optimized compound (optimized specifically for T. brucei inhibition) has been reported 
(LmNMT IC50, 0.002 µM), rather than data from the series of compounds. 
Included in the study, 5 crystal structures with bound pyrazole sulfonamides inhibitors 
are reported. However, T. brucei crystallization has not been reported, and the authors utilized 
LmNMT as a surrogate model for TbNMT, but did not discuss SAR implications of these 
compounds regarding antileishmanial development. Nevertheless, a wide range of analogs has 
been studied, and a close correlation between NMT inhibition and T. brucei parasite inhibition 
has been established (Figure 12). 
 
Figure 12: TbNMT inhibition correlates to T. brucei parasite inhibition. 
Image used with permission from Frearson, J. A.; Brand, S.; McElroy, S. P.; Cleghorn, L. A.; Smid, O.; 
Stojanovski, L.; Price, H. P.; Guther, M. L.; Torrie, L. S.; Robinson, D. A.; Hallyburton, I.; Mpamhanga, C. P.; 
Brannigan, J. A.; Wilkinson, A. J.; Hodgkinson, M.; Hui, R.; Qiu, W.; Raimi, O. G.; van Aalten, D. M.; Brenk, R.; 
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Gilbert, I. H.; Read, K. D.; Fairlamb, A. H.; Ferguson, M. A.; Smith, D. F.; Wyatt, P. G., N-Myristoyltransferase 
inhibitors as new leads to treat sleeping sickness. Nature 2010, 464 (7289), 728-732. 
 
Much like the benzofuran NMT inhibitors, the series of pyrazole sulfonamides inhibitors 
has also been patented.
105
 Similar to benzofurans, the pyrazole sulfonamides have been tested 
against LmNMT via SPA assay, as described in the patent, yet these results are unreported in the 
original paper. Inclusion of LmNMT inhibition data is far more limited than corresponding 
TbNMT data - only ~40 compounds of the total screen were also assayed for LmNMT inhibition. 
5.1.3 Quinolines 
Recently, a novel series of quinoline compounds has been discovered to inhibit P. vivax via high 
throughput screening. Structurally similar hits within the original screening set were tabulated, 
and yielded a concise SAR. This study culminated in a PvNMT inhibitor with a 2.9 µM IC50 in 
the enzymatic assay. A binding mode has also been elucidated via crystallography (PDB: 4A95, 
Figure 13). In comparison with other known inhibitors of CaNMT and TbNMT, the quinoline 
series occupies a slightly different area of the binding pocket. 
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Figure 13: Structure overlay of inhibitor species. 
Quinoline shown in green, benzofuran in orange, pyrazole sulfonamide in blue.  
Image used with permission from Goncalves, V.; Brannigan, J. A.; Whalley, D.; Ansell, K. H.; Saxty, B.; Holder, A. 
A.; Wilkinson, A. J.; Tate, E. W.; Leatherbarrow, R. J., Discovery of Plasmodium vivax N-myristoyltransferase 
inhibitors: Screening, synthesis, and structural characterization of their binding mode. J Med Chem 2012, 55 (7), 
3578-3582. Copyright 2012 American Chemical Society. 
5.1.4 Peptide/peptidomimetics 
Peptide-based and peptidomimetic NMT inhibitors have been reported for C. albicans, and P. 
falciparum.
106-109
 Detailed SAR is more limited than for small molecule inhibitors, yet activity is 
similarly impressive, with as low as 0.04 µM IC50 against CaNMT. Notably, peptide and 
peptidomimetic inhibitors can take advantage of the high degree of NMT substrate specificity, 
with a maximum selectivity of 2200-fold demonstrated in CaNMT over Hs1NMT. Structural 
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characterization of a peptide bound to S. cerevisiae  (PDB: 1IID) has been achieved, and analysis 
of >100 synthetic peptides has been performed to determine preferred amino acid composition 
for binding affinity along an 8 residue synthetic peptide. 
 33 
6.0  FUTURE PROSPECTS IN ANTILEISHMANIAL DEVELOPMENT 
Existing infrastructure for design, synthesis, and screening of L. donovani inhibitors can be better 
utilized for NMT-inhibitor-based drug discovery. A simple, comprehensive improvement to 
existing antileishmanial design would be the addition of NMT assay screening of target-free hits. 
By testing a greatly reduced number of compounds, a minimal amount of complexity is added to 
an existing screening campaign. Compounds that do not inhibit NMT may be studied and 
optimized as with any other target-free screening. Targets shown to inhibit NMT activity may be 
better optimized using target-based methodologies. In either case, further use of secondary 
screening can be carried out to better identify lead-like compounds. 
 The relevance of a target-based drug development methodologies for antileishmanials 
warrants discussion.
110-112
 Historically, the increase in computational power, and knowledge of 
genetics and proteomics has made target-based screening appear as an encouraging method for 
drug discovery. However, in practice, target-based drug design involves assumptions about 
mechanism of action, identification and validation of a drug target, and sometimes complex 
interactions between a disease and the body. Target-free screening avoids these pitfalls by 
exclusively focusing on the observed drug efficacy. In the case of N-myristoyltransferase as a 
target for visceral leishmaniasis treatment, the enzyme sidesteps these barriers. Crystal structures 
with known inhibitors and enzymatic assay provide an immediate link to compare results of the 
two methods between themselves, and between data associated with cellular assays. Transgenic 
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parasites null for the NMT-encoding gene in both L. major and L. donovani have demonstrated 
the necessity for NMT enzyme expression. The parasite biology with respect to NMT inhibition 
is well understood, and selective inhibition over human isozymes has been demonstrated. As an 
additional metric for compound screening and triage, LELP considerations may be applied to 
compound-sets. Overall, NMT presents itself as a well characterized enzyme, suitable for target-
based development.  
 Optimization of existing NMT inhibitors via a piggyback approach is the most immediately 
accessible option for antileishmanial development. Existing SAR and crystallographic data for 
other species provide a comparable framework for antileishmanial design and synthesis.  
 Peptide and peptidomimetics, in particular, offer a unique route to Leishmania inhibition, 
with the potential for high specificity toward LdNMT over HsNMT, minimal toxicity, and easy 
library synthesis of analogs via peptide coupling methods. Kinetic and inhibition studies of 
known NMT-inhibiting synthetic peptides and peptidomimetics on L. donovani NMT may be a 
first step, considering similarities between studied yeast NMT and Leishmania NMT. Significant 
differences between the proteins occur on the opposite face of the protein and CoA binding sites, 
and these differences are not purported to alter protein function, offering direct comparison of 
bound ScNMT inhibiting protein with the LmNMT crystal structure (Figure 14).
47
 Secondary 
screening of drug metabolism is also necessary to help overcome rapid metabolism commonly 
associated with peptide based drugs.
113
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Figure 14: Overlay of peptide and small molecule NMT inhibitors. 
Peptide (green) from ScNMT crystal structure (PDB: 1IID), inhibitor (orange) and enzyme (pink) from 
LmNMT crystal structure (PDB: 4A2Z). Image used with permission form Brand, S.; Cleghorn, L. A.; McElroy, S. 
P.; Robinson, D. A.; Smith, V. C.; Hallyburton, I.; Harrison, J. R.; Norcross, N. R.; Spinks, D.; Bayliss, T.; Norval, 
S.; Stojanovski, L.; Torrie, L. S.; Frearson, J. A.; Brenk, R.; Fairlamb, A. H.; Ferguson, M. A.; Read, K. D.; Wyatt, 
P. G.; Gilbert, I. H., Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med 
Chem 2012, 55 (1), 140-152. Copyright 2011 American Chemical Society. 
 
 Quinoline-based NMT inhibitors may also serve as a promising source of piggyback 
development candidates. Initially, screening of the P. vivax hits against L. donovani NMT can 
provide the first step to understanding the efficacy of this class of compounds against the 
Leishmaniases. Synthesis of these quinolines is well established to allow for further SAR studies 
and optimization.
88
 Notably, the nitrile-bearing thioether is attached last, allowing for relatively 
easy synthesis of relevant analogs for SAR studies (Figure 15). Visually, the binding pocket is 
not fully utilized by the quinoline analogs, but the nitrile group shares some overlap with other 
inhibitor classes. Replacement of the nitrile group with other potent pharmacophores may yield 
an increase in both activity and selectivity by utilizing a larger surface of the binding site. 
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 Existing SAR and synthetic routes to benzofurans, benzothiophenes, and pyrazole 
sulfonamides are extremely well established, and offer insight towards synthesis of new analogs. 
Synthetic routes to these compounds are relatively simple, with numerous points to facilitate 
combinatorial synthesis, or substitution of bioisosteric fragments. For example, pyrazole 
sulfonamides are accessible in minimal steps, with orthogonal steps to introduce additional 
moieties or substitutions (Figure 16).
103
  
 
Figure 16: Pyrazole sulfonamide synthesis. 
 Inhibitors specific to L. donovani NMT have been identified via high throughput 
enzymatic assay. Re-assay of structurally similar hits can provide a direction for future SAR 
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study, and synthesis of analog compounds is the next logical step for development and 
optimization of these compound classes. Synthetic routes to these specific compounds are not 
available via literature methods, but adaptations of existing methodologies should suffice. 
Biphenyl derivatives are readily synthesized from Suzuki-coupling of substituted aryl groups.
114
 
Piperidinylindoles are easily synthesized from a corresponding indole starting material.
115
 Chiral 
acylpyrrolidones are commercially available with a variety of aromatic substitutions and other 
pyrrolidines may be synthesized using a variety of established procedures.
116-119
 Notably, 3,4-
disubstituted pyrrolidines may be diastereoselectively synthesized from corresponding ethyl 
cinnamate analogs,
120
 followed by mild, selective N-demethylation.
121
 Subsequent coupling with 
commercially available, or readily synthesized, amino-substitued fragments by amide bond 
formation complete the full analog synthesis (Figure 17). Similarly substituted thienopyrimidines 
have been synthesized as treatments for hematological malignancies and as calcium channel 
blockers (Figure 18).
122-124
 In all cases, synthetic methods allow for easy introduction of 
structural variety, allowing for combinatorial synthesis of a variety of analogs. 
 
Figure 17: Pyrrolidine synthesis and acylpyrrolidine retrosynthesis. 
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Figure 18: Thienopyrimidine retrosynthesis. 
 
Finally, purely in silico methods may provide the easiest route for screening large 
compound libraries. While there is currently a lack of computer based drug design toward 
antileishmanials, selecting NMT as a target offers a simple, robust approach for development. 
Preliminary screening in silico can be accomplished through tandem screening of compounds 
against Leishmania and human NMT isozymes. This can be done with relatively little computing 
power (dedicated desktop as opposed to multicore servers) and at low cost (several free docking 
programs offer comparable docking performance to commercial software suites).
125-126
 Any 
molecular library may be screened, with the substantial ZINC database being an excellent 
starting point.
127
 Docking may be validated based on comparison with ligand positions in crystal 
structures, and by NMT enzyme assay of top hits. Likewise, existing SAR studies may be 
applied to provide extensive training datasets for validation of in silico methods. Computational 
methods may be inserted at any point of NMT-based antileishmanial discovery to achieve an 
optimal relationship between screening, validation, and generation of new compounds to test. 
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7.0  CONCLUSIONS 
The global disease burden and lack of sufficient clinical treatments warrant further investigation 
of antileishmanial compounds. N-myristoyltransferase has been demonstrated as a promising 
target for development of drugs treating leishmaniasis, particularly visceral leishmaniasis. 
Unfortunately, the current body of research on NMT-specific leishmania inhibitors is limited. In 
this case, existing target-free screening techniques may be easily combined to include screening 
for NMT inhibitors. The body of research on NMT inhibition in similar parasite and fungal 
species is thorough, with detailed SAR and crystallographic supporting evidence of binding 
modes on highly similar molecular targets. This offers an excellent starting point for piggyback 
development of Leishmania-specific NMT inhibitors. Of the few specific NMT inhibitors of L. 
donovani shown, no optimization has been performed on the parent chemical scaffolds, offering 
an opportunity to determine efficient syntheses, and relevant SAR for these compounds. Finally, 
in silico methods may be applied through out, in tandem with enzymatic assay results. In this 
manner, more efficient drug discovery methods may be accomplished, regardless of initial 
development method. The currently limited state of NMT-inhibitor development has been 
discussed, within the context of more expansive methods, applications, and relevant studies. 
Although there is a noticeable gap between these similar areas of research, several solutions have 
been proposed to further study of NMT inhibition of L. donovani.  
 40 
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